News
New monoclonal antibody developed that can target proteins inside cancer cells
Researchers have discovered a unique monoclonal antibody that can effectively reach inside a cancer cell, a key goal for these important anticancer agents, since most proteins that cause cancer or are associated with cancer are buried inside cancer...
News
Shire scquires Premacure AB
Shire plc has acquired Premacure AB of Uppsala, Sweden, a privately held biotechnology company developing a protein replacement therapy, currently in Phase II development, for the prevention of retinopathy of prematurity (ROP). ROP is a rare and potentially...
News
American College of Cardiology and Boehringer Ingelheim collaborate to advance physician education
In parallel with the American College of Cardiology (ACC) Scientific Sessions in San Francisco, initial results have been released from a physician educational programme being undertaken to rectify misunderstandings on stroke prevention in atrial fibrillation (AF) in China....
News
Internet searches can identify drug safety issues well ahead of public alerts
The authors base their findings on an analysis of the anonymised search logs of millions of US web users, who agreed to install a browser add-on and share their online searches with Microsoft throughout 2010. The researchers developed...
News
The key to heart failure, new therapies on horizon
Some 5.8 million Americans suffer from heart failure, a currently incurable disease. But scientists at Temple University School of Medicine's (TUSM) Center for Translational Medicine have discovered a key biochemical step underlying the condition that could aid the...
News
Discovery opens door to new drug options for serious diseases
Researchers have discovered how oxidative stress can turn to the dark side a cellular protein that's usually benign, and make it become a powerful, unwanted accomplice in neuronal death. This finding, reported in Proceedings...
News
HPS2-THRIVE trial: Side-effects cause a quarter of heart patients to stop treatment
The largest randomised study of the vitamin niacin in patients with occlusive arterial disease (narrowing of the arteries) has shown a significant increase in adverse side-effects when it is combined with statin treatment. Results...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read